ClinicalTrials.gg
RecruitingNCT06000956Updated Nov 21, 2024

A Study of Comparing Overall Improvement of Patients With Spondyloarthritis Treated With Jitongning Tablets and Placebo

A Phase 3 interventional study of Jitongning tablets and a simulated agent of Jitongning tablets in Ankylosing Spondylitis, sponsored by Tasly Pharmaceutical Group Co., Ltd. Recruiting at 10 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Tasly Pharmaceutical Group Co., Ltd (part of China Resources Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 76 studies in Spondylitis, Ankylosing with a site in China — 19 open to participants now, 22 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
11th of 62
408 · median 150
Started
2023
with 6 others
Phase 3
18 of 76
4 open now
Primary completion
2026-12
later than 7 of 21 live
Registered
52nd of 76
by date

Among the 76 studies in Spondylitis, Ankylosing with a site in China, this one is the 11th largest by planned enrollment of the 62 interventional ones that give a count, is one of 7 that started in 2023, is one of 18 in phase 3, reaches primary completion later than 7 of the 21 other live ones, and was the 52nd registered.

Spondylitis, Ankylosing

534 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 76 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 62 Spondylitis, Ankylosing studies recruiting now, 24 (39%) set no upper age limit and 32 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is evaluating the efficacy and safety of Jitongning tablets in participant population. The main questions it aims to answer are:

  • Based on the proportion of participants who achieved improvement in ASAS20, evaluate whether the efficacy of Jitongning tablets is superior to placebo in active ax-SpA adult participants.
  • Evaluate the efficacy of Jitongning tablets in improving other key functions and symptom outcomes.
  • Evaluating the safety of Jitongning tablets in adult ax-SpA participants. Participants will

    1. take orally Jitongning tablets or a simulated agent of Jitongning tablets.
    2. Receive examinations and follow-up visits.
03

Conditions studied

  • Ankylosing Spondylitis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following standards must be met:

  1. Age range from 18 to 65 years old (including 18 and 65 years old), regardless of gender;
  2. Meets the diagnostic criteria for axial osteoarthritis recommended by ASAS in 2009, and the condition is in an active phase. The criteria for determining disease activity are to meet two criteria: Bass ankylosing spondylitis disease activity index (BASDAI) ≥ 40mm (0-100mm, evaluated using VAS); Spinal pain score ≥ 40mm (0-100mm, evaluated using VAS);
  3. Conforming to the traditional Chinese medicine syndrome differentiation standards for kidney yang deficiency and blood stasis obstruction syndrome;
  4. CT examination of sacroiliac arthritis grades I (A) to II (B) (both included);
  5. Human leukocyte antigen B27 (HLA-B27) is positive;
  6. Elevated C-reactive protein (CRP)/hypersensitive C-reactive protein (hsCRP) and/or erythrocyte sedimentation rate (ESR);
  7. Voluntarily participate in this clinical trial and sign an form.

Exclusion criteria

Exclusion Criteria:

Those who meet any of the following criteria cannot be included in this experiment:

  1. Received non-steroidal anti-inflammatory drugs within 2 weeks before enrollment;
  2. Within 4 weeks before enrollment, he received traditional Chinese patent medicines and simple preparations or traditional Chinese medicine decoction, chemical drugs (such as sulfasalazine, methotrexate, leflunomide, hydroxychloroquine, cyclophosphamide, azathioprine, etc.), opioid analgesics (such as methadone, morphine, etc.), JAK inhibitor drugs (such as tofatib, etc.), and systemic treatment;
  3. Received spinal or joint surgery treatment within 8 weeks prior to enrollment;
  4. Within 12 weeks prior to enrollment, biological agents with therapeutic effects on spinal arthritis have been used;
  5. Within 6 months prior to enrollment, corticosteroid injections were received into the joint cavity or spine/paravertebral area;
  6. CT indicates disappearance of sacroiliac joint space or complete spinal rigidity;
  7. Subjects diagnosed with other rheumatic immune system diseases or immune deficiency syndrome, such as active ulcerative colitis, psoriasis, uveitis, etc;
  8. Those who have fertility requirements within six months;
  9. Pregnant or lactating women;
  10. Suspected or actual drug, substance, or alcohol abuse;
  11. Within 3 months prior to the trial or currently participating in clinical trials;
  12. Serious heart, liver, kidney, brain, mental, and neurological disorders that affect and/or expression or observation of adverse events;
  13. Abnormal liver function (elevated levels of alanine or above the values); Abnormal renal function (serum creatinine levels above the upper limit of normal values);
  14. The researchers believe that it is not suitable to participate in this experiment.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
408 participants (estimated)

Study arms

  • Experimental
    Jitongning tablets

    Drug: Jitongning tablets

  • Placebo comparator
    a simulated agent of Jitongning tablets

    Drug: a simulated agent of Jitongning tablets

Interventions

  • DrugJitongning tablets

    The participants took orally three tablets of Jitongning tablets, twice a day, for 8 consecutive weeks.

  • Druga simulated agent of Jitongning tablets

    The participants took orally three tablets of a simulated agent of Jitongning tablets, twice a day, for 8 consecutive weeks.

06

What researchers measure

Primary outcomes

  1. ASAS20

    Proportion of subjects who achieved improvement in ASAS20(Assessment of Spondylarthritis International Society) at week 8 of treatment. The ASAS Improvement Criteria contains the following 4 assessment domains: 1. Physical function, by BASFI (Bath Ankylosing Spondylitis Functional Index); 2. Spinal pain, by Spinal Pain Scale; 3. Overall assessment of the condition in the past week, by PGA (Patient Global Assessment) 4. Inflammatory activity, by the last 2 items of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) were averaged. ASAS 20% response criteria (ASAS 20): 1. 3 of the above 4 items have at least ≥20% improvement and improved ≥ 10 mm in 0-100mm score; 2. Moreover, there was no deterioration in 1 item that did not achieve a 20% improvement from baseline.

    Time frame: 8 weeks

Secondary outcomes

  1. ASAS20

    Proportion of subjects who achieved improvement in ASAS20 at week 4 of treatment.The ASAS Improvement Criteria contains the following 4 assessment domains: 1. Physical function, by BASFI (Bath Ankylosing Spondylitis Functional Index); 2. Spinal pain, by Spinal Pain Scale; 3. Overall assessment of the condition in the past week, by PGA (Patient Global Assessment) 4. Inflammatory activity, by the last 2 items of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) were averaged. ASAS 20% response criteria (ASAS 20): 1. 3 of the above 4 items have at least ≥20% improvement and improved ≥ 10 mm in 0-100mm score; 2. Moreover, there was no deterioration in 1 item that did not achieve a 20% improvement from baseline.

    Time frame: 4 weeks

  2. ASAS40

    Proportion of subjects who achieved improvement in ASAS40 at week 8 of treatment.The ASAS Improvement Criteria contains the following 4 assessment domains: 1. Physical function, by BASFI (Bath Ankylosing Spondylitis Functional Index); 2. Spinal pain, by Spinal Pain Scale; 3. Overall assessment of the condition in the past week, by PGA (Patient Global Assessment) 4. Inflammatory activity, by the last 2 items of BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) were averaged. ASAS 40% response standard (ASAS 40): 1. 3 of the above 4 items have at least ≥20% improvement and improved ≥ 20 mm in 0-100mm score; 2. Moreover, there was no deterioration in 1 item that did not achieve a 40% improvement from baseline.

    Time frame: 8 weeks

  3. spinal pain scale

    Change from baseline in score of spinal pain at week 8 of treatment.The highest score on the scale is 100mm and the lowest is 0mm, and the higher the score, the more severe the condition.

    Time frame: 8 weeks

  4. BASFI

    Change from baseline in score of BASFI(Bath Ankylosing Spondylitis Functional Index) at week 8 of treatment.The highest score on the scale is 100mm and the lowest is 0mm, and the higher the score, the more severe the condition.

    Time frame: 8 weeks

  5. PGA

    Change from baseline in score of PGA(Patient Global Assessment) at week 8 of treatment.The highest score on the scale is 100mm and the lowest is 0mm, and the higher the score, the more severe the condition.

    Time frame: 8 weeks

  6. BASDAI

    Change from baseline in score of BASDAI(Bath Ankylosing Spondylitis Disease Activity Index) at week 8 of treatment.The highest score on the scale is 100mm and the lowest is 0mm, and the higher the score, the more severe the condition.

    Time frame: 8 weeks

  7. Traditional Chinese medical Syndrome Points

    Change from baseline in score of traditional Chinese medical Syndrome at week 8 of treatment.The scale has a maximum score of 36 points and a minimum score of 0 points, with lower scores indicating milder TCM symptoms.

    Time frame: 8 weeks

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Dec 2026, 38 months after the start.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's planned 38 months is above that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2023
First posted
Aug 21, 2023
StartActual
Sep 11, 2023
Primary completionEst.
Dec 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06000956
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Sep 11, 2023
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 21, 2024

Study contacts

Wei Liu
Contact
fengshiliuwei@163.com
022-27432680

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion